Cramer's 'Mad Money' Recap: Next Week's Game Plan
Cramer said the fiscal cliff is indeed a serious issue, but it may not mean the end of stocks as we know them.
That's why Cramer said he'll be watching for movement on the fiscal cliff issue, but he'll also be paying attention to a plethora of earnings and economic data during next week's trading.
Then on Tuesday, a slew of retailers including Dick's Sporting Goods (DKS) , Home Depot (HD) , Michael Kors (KORS) , Saks (SKS) and TJX Stores (TJX) will be reporting. Each will tell a story said Cramer, whether its Dick's with outdoor apparel, Home Depot's reaction to Hurricane Sandy or Michael Kors and Saks with a read on high end fashions.
Wednesday brings earnings from more retailers, including Abercrombie & Fitch (ANF) , Hot Topic (HOTT) , Staples (SPLS) , Williams-Sonoma (WSM) and Petsmart (PETM) . Cramer said he only expects good things from Williams-Sonoma and perhaps Petsmart.
Turning to Thursday, it's Dollar Tree (DLTR) , Wal-Mart (WMT) , Gap Stores (GPS) , Target (TGT) and Ross Stores (ROST) taking center stage. Cramer said that he'd be a seller ahead of Wal-Mart, Gap and Target as these retailers could be hurt by Hurricane Sandy. He said Ross may see a bounce off its earnings.
Put Excitement in Your Portfolio
In a grim market like this one, investors need some stocks in their portfolios to keep them excited, Cramer told his audience, which is why speculating on biotech is just what the doctor ordered. Cramer said a stock like Tesaro (TSRO) just may fit the bill.
Tesaro has not been a public company for very long, noted Cramer, but it comes with great bloodlines. The company's management already has a proven track record of building companies and selling them for hefty profits. So far, shares of Tesaro are up a modest 11% from the initial public offering price of $13.50 a share.
Tesaro is an oncology-focused company that aims to help improve the lives of cancer patients. It's first drug, Rolapitant, was licensed from Opko Health (OPK) for a terrific price and is now in Phase III testing. That drug helps prevent nausea in patients undergoing chemotherapy.
Tesaro also has two other drugs in early stage testing, one to directly attack tumors and the other to treat specific lung cancers. With over $138 million in cash on its books and no debt, Cramer said that Tesaro is really a $10 stock with a very promising future.